Corpus overview


Overview

MeSH Disease

Human Phenotype

Transmission

Seroprevalence
    displaying 1 - 6 records in total 6
    records per page




    Diagnosis of Coronavirus disease MESHD by measuring serum SERO concentrations of IL-6 and blood SERO Ferritin

    Authors: Parviz Yazdanpanah; Farzad Vafaei; Saeed Javdansirat; Jalal pouranfard; Sajad Afrouz

    doi:10.21203/rs.3.rs-74750/v1 Date: 2020-09-09 Source: ResearchSquare

    Objectives: Coronavirus disease MESHD 2019 (COVID-19) associated by infection MESHD and high death rate. The unresolved questions about the fatality rate of COVID-19 is most probably related to cytokine storm syndrome. There is currently no specific medication. Understanding the pathogenic pathway of this disease will lead to production of treatment and decreases of death MESHD rate. The aim of this study is to investigate changes of peripheral blood SERO parameters (Interleukin-6 and Ferritin) in COVID-19 patients, which may be beneficial in the management of patients.Methods: In this case-control study, we collected data of 270 subjects in two groups including 133 patients with severe type COVID-19 (case) and 137 patients with nonsevere (control) between March 20 and May 21, 2020, and the clinical symptoms and inflammatory indications of patients diagnosed by laboratory test in Shahid Jalil hospital of Yasuj University of medical Sciences were collected to explore potential markers for disease monitoring. The data were analyzed by SPSS software version 20. Descriptive statistics, T-test and bivariate correlation tests were used to analyze. Results: The enrolled COVID-19 patients consisted of 53.4% males TRANS and 46.6% females TRANS with the medium age TRANS of 45.56±18.55 years and there were 50.04% males TRANS and 49.6% females TRANS with the medium age TRANS of 45.59±17.0 years for non COVID-19 patients. There was no significant difference in the age TRANS and sex ratio between two population under study. The proportion interstitial abnormalities MESHD evidenced by CT imaging in COVID-19 patients was 91.0%, while, 4.4% abnormalities was found in non COVID-19 patients. The frequency of positive RT-PCR test for case and control groups were 88.0% and 3.6%, respectively. The mean IL-6 and Ferritin levels and hematological parameters in two groups of patients with COVID-19 and non- COVID-19, were significantly different across all comparisons.There was a direct positively correlated between serum SERO level of IL-6, Ferritin levels and hematological parameters including WBC, Lymphocytes, Neutrophils and Hb, except for platelets (negatively correlate),  with COVID-19. Conclusions: In conclusion, inflammatory markers specifically IL-6 and Ferritin and hematological parameters (WBC, Lymphocytes, Neutrophils, Platelet and Hb) were correlated with the severity of COVID-19. Measurement of IL-6, Ferritin and hematological MESHD indices might be workable tests to diagnosis and prognosis of patients with COVID-19. 

    Intranasal Exposure of African Green Monkeys to SARS-CoV-2 Results in Acute Phase Pneumonia HP With Shedding and Lung Injury Still Present in the Early Convalescence Phase

    Authors: Tom Geisbert; Robert Cross; Krystle Agans; Abhishek Prasad; Viktoriya Borisevich; Courntey Woolsey; Daniel Deer; Natalie Dobias; Joan Geisbert; Karla Fenton

    doi:10.21203/rs.3.rs-50023/v1 Date: 2020-07-28 Source: ResearchSquare

    We recently reported the development of the first African green monkey (AGM) model for COVID-19 based on a combined liquid intranasal (i.n.) and intratracheal (i.t.) exposure to severe acute respiratory syndrome coronavirus 2 MESHD (SARS-CoV-2). Here, we followed up on this work by assessing an i.n. particle only route of exposure using the LMA mucosal atomization device (MAD). Six AGMs were infected with SARS-CoV-2; three animals were euthanized near the peak stage of virus replication (day 5) and three animals were euthanized during the early convalescence period (day 34). All six AGMs supported robust SARS-CoV-2 replication and developed respiratory disease MESHD. Evidence of coagulation dysfunction MESHD as noted by a transient increases in aPTT and circulating levels of fibrinogen was observed in all AGMs. The level of SARS-CoV-2 replication and lung pathology was not quite as pronounced as previously reported with AGMs exposed by the combined i.n. and i.t. routes; however, SARS-CoV-2 RNA was detected in nasal swabs of some animals as late as day 15 and rectal swabs as late as day 28 after virus challenge. Of particular importance to this study, all three AGMs that were followed until the early convalescence stage of COVID-19 showed substantial lung pathology at necropsy as evidenced by multifocal chronic interstitial pneumonia MESHD pneumonia HP and increased collagen deposition in alveolar MESHD walls despite the absence of detectable SARS-CoV-2 in any of the lungs of these animals. These findings are consistent with human COVID-19 further demonstrating that the AGM faithfully reproduces the human condition.

    Intranasal exposure of African green monkeys to SARS-CoV-2 results in acute phase pneumonia HP pneumonia MESHD with shedding and lung injury MESHD still present in the early convalescence phase

    Authors: Robert W Cross; Krystle N Agans; Abhishek N Prasad; Viktoriya Borisevich; Courtney Woolsey; Daniel J Deer; Natalie S Dobias; Joan B Geisbert; Karla A Fenton; Thomas W Geisbert

    doi:10.21203/rs.3.rs-50023/v2 Date: 2020-07-28 Source: ResearchSquare

    We recently reported the development of the first African green monkey (AGM) model for COVID-19 based on a combined liquid intranasal (i.n.) and intratracheal (i.t.) exposure to severe acute respiratory syndrome coronavirus 2 MESHD (SARS-CoV-2). Here, we followed up on this work by assessing an i.n. particle only route of exposure using the LMA mucosal atomization device (MAD).  Six AGMs were infected with SARS-CoV-2; three animals were euthanized near the peak stage of virus replication (day 5) and three animals were euthanized during the early convalescence period (day 34).  All six AGMs supported robust SARS-CoV-2 replication and developed respiratory disease MESHD. Evidence of coagulation dysfunction MESHD as noted by a transient increases in aPTT and circulating levels of fibrinogen was observed in all AGMs. The level of SARS-CoV-2 replication and lung pathology was not quite as pronounced as previously reported with AGMs exposed by the combined i.n. and i.t. routes; however, SARS-CoV-2 RNA was detected in nasal swabs of some animals as late as day 15 and rectal swabs as late as day 28 after virus challenge. Of particular importance to this study, all three AGMs that were followed until the early convalescence stage of COVID-19 showed substantial lung pathology at necropsy as evidenced by multifocal chronic interstitial pneumonia MESHD pneumonia HP and increased collagen deposition in alveolar MESHD walls despite the absence of detectable SARS-CoV-2 in any of the lungs of these animals.  These findings are consistent with human COVID-19 further demonstrating that the AGM faithfully reproduces the human condition.

    COVID-19-induced acute respiratory failure HP respiratory failure MESHD: an exacerbation of organ-specific autoimmunity HP?

    Authors: Daniel Gagiannis; Julie Steinestel; Carsten Hackenbroch; Michael Hannemann; Vincent G Umathum; Niklas Gebauer; Marcel Stahl; Hanno M Witte; Konrad Steinestel

    doi:10.1101/2020.04.27.20077180 Date: 2020-05-01 Source: medRxiv

    Background: Understanding the pathophysiology of respiratory failure HP respiratory failure MESHD (ARDS) in coronavirus disease MESHD 2019 (COVID-19) patients is of utmost importance for the development of therapeutic strategies and identification of risk factors. Since we observed clinical and histopathological similarities between COVID-19 and lung manifestations of connective tissue disease (CTD-ILD) in our clinical practice, aim of the present study is to analyze a possible role of autoimmunity HP in SARS-CoV-2-associated respiratory failure HP respiratory failure MESHD. Methods: In this prospective, single-center trial, we enrolled 22 consecutive patients with RT-PCR-confirmed SARS-CoV-2 infection MESHD hospitalized in March and April, 2020. We performed high-resolution computed tomography (HR-CT) and full laboratory testing including autoantibody (AAB) screening (anti-ANA, SS-B/La, Scl-70, Jo-1, CENP-B, PM-Scl). Transbronchial biopsies as well as post mortem tissue samples were obtained from 3 and 2 cases, respectively, and subsequent histopathologic analysis with special emphasis on characterization of interstitial lung disease MESHD was performed. Results: Twelve of 22 patients (54.5%) were male TRANS and median age TRANS was 69.0 (range: 28-88). 11 (50.0%) patients had to be undergo intensive care unit (ICU) treatment. Intubation with ventilation was required in 10/22 cases (46%). Median follow-up was 26 days. Clinical and serological parameters were comparable to previous reports. Radiological and histopathological findings were highly heterogeneous including patterns reminiscent of CTD-ILD. AAB titers [≥]1:100 were detected in 10/11 (91.9%) COVID-19 patients who required ICU treatment, but in 4/11 (36.4%) patients with mild clinical course (p=0.024). Patients with AABs tended to require invasive ventilation and showed significantly more severe complications (64.3% vs. 12.5%, p=0.031). Overall COVID-19-related mortality was 18.2% among hospitalized patients at our institution. Conclusion: Our findings point out serological, radiological and histomorphological similarities between COVID-19-associated ARDS and acute exacerbation of CTD-ILD. While the exact mechanism is still unknown, we postulate that SARS-CoV-2 infection MESHD might trigger or simulate a form of organ-specific autoimmunity HP in predisposed patients. The detection of autoantibodies might identify patients who profit from immunosuppressive therapy to prevent the development of respiratory failure HP respiratory failure MESHD.

    Use of siltuximab in patients with COVID-19 pneumonia HP pneumonia MESHD requiring ventilatory support

    Authors: Giuseppe Gritti; Federico Raimondi; Diego Ripamonti; Ivano Riva; Francesco Landi; Leonardo Alborghetti; Marco Frigeni; Marianna Damiani; Caterina Micò; Stefano Fagiuoli; Roberto Cosentini; Ferdinando Luca Lorini; Lucia Gandini; Luca Novelli; Jonathan P Morgan; Benjamin M.J. Owens; Karan Kanhai; Gordana Tonkovic Reljanovic; Marco Rizzi; Fabiano Di Marco; Alessandro Rambaldi

    doi:10.1101/2020.04.01.20048561 Date: 2020-04-03 Source: medRxiv

    Background Severe COVID-19 is characterised by interstitial pneumonia MESHD pneumonia HP and hyperinflammation, with elevated levels of pro-inflammatory cytokines, such as IL-6. Effective treatments are urgently needed, and IL-6 is a rational target to reduce hyperinflammation. Methods An observational, control cohort, single-centre study initiated at the Papa Giovanni XXIII Hospital in Bergamo, Italy included patients with COVID-19 confirmed by a nasopharyngeal swab positive for severe acute respiratory syndrome coronavirus MESHD 2 RNA and interstitial pneumonia MESHD pneumonia HP requiring ventilatory support. Patients were treated with either best supportive care and siltuximab or best supportive care alone. Propensity score matching was applied to minimise differences in baseline covariates between patient cohorts. The main outcome was mortality in siltuximab-treated patients compared with patients in the matched-control cohort. This study (Siltuximab in Severe COVID-19, SISCO) is registered with ClinicalTrials.gov, identifier NCT04322188. Findings Thirty patients received siltuximab, while 188 control patients received only best supportive care. Siltuximab-treated patients were matched to 30 control patients using the propensity score analysis of baseline covariates. The 30-day mortality rate was significantly lower in the siltuximab-treated than the matched-control cohort patients (HR 0.462, 95% CI 0.221-0.965); p=0.0399). The mean follow-up was 33.3 days (range 7-58 days) for the siltuximab-treated patients and 22.8 days (range 2-45 days) for the control cohort. Sixteen siltuximab-treated patients were discharged from hospital, four remained on mechanical ventilation, and 10 patients died. Interpretation Patients with rapidly progressing COVID-19 respiratory failure HP respiratory failure MESHD requiring ventilatory support may benefit from treatment with siltuximab to reduce mortality and cytokine-driven hyperinflammation associated with severe disease. These findings require validation in a randomised controlled clinical trial. Funding Papa Giovanni XXIII Hospital and the Italian Association for Cancer MESHD Research funded the study. EUSA Pharma supplied siltuximab, and provided funding for data collection, analysis, and development of the publication.

    The potential role of IL-6 in monitoring coronavirus disease MESHD 2019.

    Authors: Tao Liu; Jieying Zhang; Yuhui Yang; Hong Ma; Zhengyu Li; Jiaoyue Zhang; Ji Cheng; Xiaoyun Zhang; Yanxia Zhao; Zihan Xia; Liling Zhang; Gang Wu; Jianhua Yi

    doi:10.1101/2020.03.01.20029769 Date: 2020-03-06 Source: medRxiv

    Abstract. Background: The outbreak of coronavirus disease MESHD 2019 (COVID-19) in Wuhan City, China spreads rapidly since December, 2019. Most patients show mild symptoms, but some of them develop into severe disease. There is currently no specific medication. The purpose of this study is to to explore changes of markers in peripheral blood SERO of severe COVID-19 patients, which may be of value in disease monitoring. Methods Clinical data of patients with nonsevere and severe type COVID-19 diagnosed by laboratory test in our institution were collected. The relationship between peripheral blood SERO cells and cytokines, clinical manifestation and outcome was analyzed. Results A total of 69 severe type COVID-19 patients were included. On admission, the median age TRANS of severe cases was 56-year old, with 52.17% female TRANS patient. The most common symptoms were fever HP fever MESHD (79.72%), cough HP (63.77%), shortness of breath MESHD (57.97%) and fatigue HP fatigue MESHD (50.72%). Diarrhea HP Diarrhea MESHD is less common. The most common comorbidity is hypertension HP hypertension MESHD. Upon admission, the proportion of bilateral pulmonary involvement and interstitial abnormalities MESHD evidenced by chest computed tomography (CT) imaging in severe cases was 60.87% and 27.54%, respectively. Compared with patients with nonsevere disease, those with severe disease showed obvious lymphocytopenia MESHD. Elevated level of lactate dehydrogenase (LDH), C-reactive protein (CRP), ferritin and D-dimer was found in most cases. Two patients (2.9%) needed transfer to the intensive care unit. Baseline immunological parameters and most of the inflammatory parameters were basically within the normal range. However, baseline interleukin-6 (IL-6) was significantly increased in severe type, which was closely related to the maximal body temperature during hospitalization and to CT findings. Baseline IL-6 was also significantly related to the increase of baseline level of CRP, LDH, ferritin and D-dimer. The increase of baseline IL-6 level suggests that it may positively correlate with the severity of COVID-19. Among the 30 severe type patients whose IL-6 was assessed before and after treatment, significant decrease in IL-6 and improved CT assessment was found in 25 patients after treatment. Whereas the IL-6 level was further increased in 3 cases, which was closely related to disease progression. It is suggested that IL-6 may be used as a marker for disease monitoring in severe COVID-19 patients. Conclusions On admission, the baseline level of IL-6, CRP, LDH and ferritin was closely related to the severity of COVID-19, and the elevated IL-6 was significantly related to the clinical manifestation of severe type patients. The decrease of IL-6 was closely related to treatment effectiveness, while the increase of IL-6 indicated disease exacerbation. Collectively, the dynamic change of IL-6 level can be used as a marker for disease monitoring in patients with severe COVID-19.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.